The Comprehensive Guide to Mitomycin 2mg Injection In the complex landscape of cytotoxic chemotherapy, Mitomycin 2mg Injection (also known as Mitomycin-C) remains an essential therapeutic tool. As a specialized pharmaceutical exporter from India, Ernest Oncology (a group of Ernest Pharmaceutical Pvt. Ltd.) provides consistent, high-quality supply chains for this potent antineoplastic agent to major medical hubs in London, New York, Sydney, and Johannesburg. Product Specifications Brand Name: Ernest-Oncology (Mitomycin) Strength: 2mg per vial Dosage Form: Lyophilized Powder for Injection / Infusion Primary Indication: Treatment of disseminated adenocarcinoma of the stomach or pancreas, and superficial bladder cancer. Storage: Store at room temperature (20°C to 25°C). Once reconstituted, the solution is stable for limited periods depending on the diluent used. Mechanism of Action: How It Works DNA Cross-linking: Upon intracellular activation, Mitomycin produces a bifunctional alkylating agent that binds to DNA. This creates stable cross-links between DNA strands, effectively “zipping“ them together. Inhibition of Synthesis: By preventing the separation of DNA strands, Mitomycin inhibits DNA replication and, to a lesser extent, RNA and protein synthesis. Cell Death: The inability of the cancer cell to replicate its genetic material leads to programmed cell death (apoptosis), particularly in fast-growing tumor cells. Therapeutic Indications & Administration Advanced Adenocarcinomas: Specifically for stomach and pancreatic cancers that have not responded to other treatments. Bladder Cancer (Intravesical): Injected directly into the bladder to treat superficial tumors and prevent recurrence after surgical resection. Ophthalmic Use: Often used off-label at very low concentrations during glaucoma surgery to prevent scarring (fibrosis). Administration Guidelines:Intravenous (IV): Must be administered by a qualified professional. Extremely careful technique is required to avoid extravasation (leaking into the skin), which can cause severe tissue necrosis. Intravesical: Administered via a catheter for localized treatment within the bladder. Clinical Side Effects & Safety Cumulative Bone Marrow Suppression: The most significant side effect is a delay in blood cell production (leukopenia and thrombocytopenia). This effect is cumulative, meaning it may become more severe with repeated doses. Renal Toxicity: A small percentage of patients may experience a rise in serum creatinine, indicating potential kidney impact. Hemolytic Uremic Syndrome (HUS): A rare but serious condition involving microangiopathic hemolytic anemia and renal failure. Common Effects: Nausea, vomiting, loss of appetite, and temporary hair loss (alopecia). Contraindications: Not recommended for patients with a known hypersensitivity to Mitomycin or those with significant coagulation disorders or existing severe bone marrow suppression. Why Source from Ernest Oncology? United Kingdom (London): Meeting the demand for cost-effective, high-quality alternatives for specialized oncology clinics. USA: Supplying bulk quantities that adhere to rigorous safety and documentation standards for clinical use. Australia: Ensuring stable access through established supply chains, including TGA-compliant “Special Access Scheme“ (SAS) requirements. South Africa: Bridging critical gaps in cancer care with affordable, high-tier pharmaceutical exports from India. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 📦 Business Type: Exporter | Bulk Supplier | Distributor 🌐 Websites: www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com www.ernestvision.com www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383
Washington, USA
08048034998
+919405476170
Chat with us
Chat with us